S4. The TAMARISK-study, a cohort study of the clinico-pathological and molecular characteristics, and the prognosis of uterine malignancies after tamoxifen  by unknown
S4. THE TAMARISK-STUDY, A COHORT STUDY OF THE CLINICO-
PATHOLOGICAL AND MOLECULAR CHARACTERISTICS, AND THE
PROGNOSIS OF UTERINE MALIGNANCIES AFTER TAMOXIFEN
Hoogendoorn WEa, Hollema Hb, Nederlof PMa, van Boven HHa, Mourits MJb,
van Leeuwen FEa. a Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX
Amsterdam, The Netherlands; b Academic Hospital Groningen, PO Box 30.001,
9700 RB Groningen, The Netherlands
Introduction: Many studies have consistently shown that long-term use of
tamoxifen is associated with an increased risk of corpus uteri cancer [1].
Furthermore, in a recent study of our own group among women with corpus
uteri cancer following breast cancer diagnosed in the Netherlands up to 1996, it
was found that the corpus uteri tumours of long-term tamoxifen users had less
favourable histology and higher International Federation of Gynecology and
Obstetrics (FIGO) stage and were more often P53-positive and oestrogen-
receptor-negative than corpus uteri tumours in women not treated with
tamoxifen [2].
The purpose of the TAMARISK (Tamoxifen Associated Malignancies: Aspects
of RISK)-study is to examine whether selective clinico-pathological character-
istics and ultimate prognosis of uterine malignancies subsequent to tamoxifen
treatment are indeed diﬀerent from those of uterine malignancies in patients not
treated with tamoxifen. In addition, we want to identify diﬀerences in protein
expression, gene expression and speciﬁc genomic aberrations in uterine tumour
samples of women with and without tamoxifen use. This may give more insight
into the mechanism of tamoxifen-induced carcinogenesis.
Patients and Methods: For this study, a cohort of patients with a uterine
malignancy following breast cancer is being formed. The study has a
retrospective and a prospective part. For the retrospective part, patients
diagnosed 1996–2001 (n = 300) were identiﬁed through the population-based
Netherlands Cancer Registry. Detailed information about breast cancer
treatment, gynaecological surveillance in the interval between the two
malignancies, symptoms of the uterine malignancy, results of diagnostic tests
and follow-up is abstracted from the medical records of all cases by registration
clerks of the 9 Comprehensive Cancer Centres in The Netherlands. To review the
histological diagnosis, tissue blocks of corpus uteri cancer will be obtained.
These tissue blocks will also be used to examine genomic aberrations by array-
comparative genomic hybridisation (CGH) and to examine hormone receptor
status and gene-expression proﬁles at the protein level using appropriate
antibodies.
For the prospective part of the study, patients (n = 90) are identiﬁed by
gynaecologists in participating hospitals. Identiﬁcation of incident cases is
necessary in order to obtain fresh tumour samples that will be used for gene
expression analysis using the micro-array (cDNA) technique. Since cases with a
uterine malignancy after breast cancer are relatively rare, it is crucial not to miss
any patients.
In cooperation with the Dutch Network and National Database for Pathology
(PALGA), a novel signalling system has been developed (see Fig. 1). The study
coordinator receives information on patients with a newly diagnosed uterine
malignancy and breast cancer in the medical history from PALGA on a weekly
basis. This gives us the opportunity to contact the pathology laboratory where
the diagnosis was made and subsequently the treating gynaecologist.
Results and conclusions: The current status of the project is as follows. For the
retrospectively selected patients diagnosed from 1996 to 2001, medical record
data are now being collected. Fifty-ﬁve out of 57 pathology laboratories have
given permission for the signalling system. Ninety-seven out of 104 Departments
of Gynaecology have agreed to participate in the prospective part of the study.
Up to March 2004, we have collected fresh frozen tissue from 52 patients.
The results so far indicate that we will be able to reach the planned number of 90
patients for the prospective part of the study. With the signalling system, we have
found a very eﬀective method for the population-based collection of fresh
tumour tissue. This system can also be of use in other studies of relatively rare
patient groups.
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Fig. 1. Schematic presentation of the signalling system through PALGA (Dutch
Network and National Database of Pathology).
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